Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies

Emerging infectious diseases (EIDs) are characterized by unpredictable incidence and clinical patterns that pose unique challenges for vaccine development. As outbreaks of Ebola virus, Zika virus, and other EIDs have occurred in the past decade, drug developers and global health organizations are turning to novel funding and clinical trial paradigms to improve epidemic preparedness. This report covers current and future challenges for the development and deployment of vaccines for EIDs, focusing on vaccine platform technology and research, funding mechanisms, and collaborative global partnerships.

Scope

GlobalData’s Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at vaccines for emerging infectious diseases in the US, Europe, Asia, and Africa.

Components of the report include:

  • Overview of EIDs – Background, drivers of transmission, and overview of key EIDs.
  • Clinical Trial Design – How vaccine for EIDs clinical trials are being designed and what regulatory strategies are being explored.
  • Vaccine Platform Technologies – How the current platform technologies for vaccines compare.
  • Pipeline Assessment for Key EIDs – What are the pipeline vaccine products in development for key EIDs.
  • Funding and Market Incentives – How vaccine development is being incentivized in the public and private spaces.
  • Global Collaborations – How global and public-private partnership organizations are supporting vaccine development.
  • Vaccine Preparedness – The current and future challenges face vaccine preparedness from a surveillance and infrastructure perspective.

Reasons to buy

Develop business strategies by understanding the global trends shaping and driving the vaccines for EIDs market

Formulate effective sales and marketing strategies by understanding the competitive landscape of various competitors in a niche therapeutic space.

Identify areas of unmet need within the vaccines for EIDs market to help drive research and development towards future market opportunities.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key funding and partnership strategies.

Companies mentioned

Bharat Biotech

Emergent Biosolution

IDT Biologika

Imutex

Inovio

Integrated Biotherapeutics

Johnson & Johnson/Janssen

GeneOne Life Science

GlaxoSmithKline

NewLink Genetics

Merck

Novartis

Novavax

Pfizer

Profectus BioSciences ...

Bharat Biotech

Emergent Biosolution

IDT Biologika

Imutex

Inovio

Integrated Biotherapeutics

Johnson & Johnson/Janssen

GeneOne Life Science

GlaxoSmithKline

NewLink Genetics

Merck

Novartis

Novavax

Pfizer

Profectus BioSciences

Sanofi Pasteur

Takeda

Themis Biosciences

Tianjin CanSino Biotechnology

Vaccitech

Valneva

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1 Table of Concents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2. Executive Summary

2.1 Key ...

Table of Contents (PowerPoint Deck)

1. Preface

1.1 Table of Concents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL Insight on Vaccines for Emerging Infectious Diseases

3. Overview of Emerging Infectious Diseases

3.1 Defining Emerging Infectious Diseases (EIDs)

3.2 Drivers of Emerging Infections & Routes of Transmission

3.3 Key EIDs

3.4 Ebola Virus Disease

3.5 Zika Virus Disease

3.6 Middle East Respiratory Syndrome (MERS) and Other EIDs

4. Clinical Trial Design

4.1 Clinical Trial Design Challenges

4.2 Randomization Units

4.3 Selection of Clinical Trial Population and Comparator

4.4 Additional Strategies for Vaccine Approvals

4.5 Unmet Needs in Clinical Trial Design

5. Vaccine Platform Technologies

5.1 Overview of Vaccine Platform Technologies

5.2 Vaccine Platforms By Stage of Development

5.3 Live-attenuated Vaccines

5.4 Viral Vector-Based Vaccines

5.5 DNA Vaccines

5.6 Whole-Inactivated Vaccines, Subunit Vaccines, and VLPs

6. Funding and Market Incentives

6.1 Funding Sources for Vaccines for EIDs

6.2 Push and Pull Incentives

6.3 Challenges for Funding of Vaccine Development

6.4 Lessons from the Ebola and Zika Outbreaks

7. Global Collaborations for Vaccine Development

7.1 Global Vaccine Development Fund and Priority Diseases

7.2 Coalition for Epidemic Preparedness Innovations (CEPI)

7.3 Vaccine Preparedness

7.4 Global Virome Project (GVP) and Other Public-Private Partnerships

8. Pipeline Vaccines for Key Emerging Infectious Diseases

8.1 Clinical Development of Vaccines for EIDs

8.2 Ebola Vaccine Pipeline

8.3 Zika Vaccine Pipeline

8.4 MERS-CoV Vaccine Pipeline

9. Surveillance and Healthcare Infrastructures

9.1 Disease Surveillance for EIDs

9.2 Logistical Challenges for Vaccine Delivery

9.3 Vaccine Preparedness

9.4 Unmet Needs in Basic Vaccine Research

10. Appendix

12.1 Sources

12.2 Methodology

12.3 Primary Research

12.4 About the Authors

12.5 About GlobalData

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

I truly appreciate your responsiveness and willingness to listen to our questions.

  GlaxoSmithKline Worldwide Business Development